Time Trends of Crohn's Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery
Brunet, Eduard (Universitat Autònoma de Barcelona. Departament de Medicina)
Vela, Emili (Servei Català de la Salut)
Melcarne, Luigi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Cleries, Montserrat (Servei Català de la Salut)
Pontes García, Caridad (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Llovet, Laura Patricia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Garcia-Iglesias, Pilar (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Gallach, Marta (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Villoria, Albert (Universitat Autònoma de Barcelona. Departament de Medicina)
Vergara, Mercedes (Universitat Autònoma de Barcelona. Departament de Medicina)
Suarez-Calvet, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina)

Date:	2020
Abstract:	Background and Aims: Data from clinical trials suggest that biological drugs may improve the outcomes in Crohn's disease (CD) by reducing the need for surgery or hospitalization. The aim of this study is to evaluate the time-trends of the use of biological drugs and other treatments for CD, and its relationship with outcomes in Catalonia. Materials and Methods: All patients with CD included in the Catalan Health Surveillance System (containing data on a population of more than 7. 5 million) from 2011 to 2017 were identified. The exposures to different treatments for inflammatory bowel disease were retrieved from electronic invoicing records. Results: Between 2011 and 2017, the use of salicylates, corticosteroids and immunosuppressive treatment fell from 28. 8% to 17. 1%, 15. 8% to 13. 7%, and 32. 9% to 29. 6%, respectively (p < 0. 001). Biological treatment use rose from 15. 0% to 18. 7% (p < 0. 001). Ostomy rates per 1000 patients/year fell from 13. 2 in 2011 to 9. 8 in 2017 (p = 0. 003), and surgical resection rates from 24. 1 to 18. 0 (p < 0. 001). The rate of CD-related hospitalizations per 1000 patients/year also fell, from 92. 7 to 72. 2 (p < 0. 001). Conclusions: Biological drug use rose from 15. 0% to 18. 7% between 2011 and 2017. During this period, we observed an improvement in the outcomes of CD patients.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Epidemiology ; Inflammatory bowel disease ; Crohn's disease
Published in:	Journal of clinical medicine, Vol. 9 Núm. 9 (setembre 2020) , p. 2896, ISSN 2077-0383

Adreça alternativa: https://publons.com/publon/34189969/
DOI: 10.3390/jcm9092896
PMID: 32911630

9 p, 788.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles